Literature DB >> 14871975

Microsatellite instability, immunohistochemistry, and additional PMS2 staining in suspected hereditary nonpolyposis colorectal cancer.

Andrea E de Jong1, Marjo van Puijenbroek, Yvonne Hendriks, Carli Tops, Juul Wijnen, Margreet G E M Ausems, Hanne Meijers-Heijboer, Anja Wagner, Theo A M van Os, Annette H J T Bröcker-Vriends, Hans F A Vasen, Hans Morreau.   

Abstract

PURPOSE: Immunohistochemistry (IHC) and microsatellite instability (MSI) analysis can be used to identify patients with a possible DNA mismatch repair defect [hereditary nonpolyposis colorectal carcinoma (HNPCC)]. The Bethesda criteria have been proposed to select families for determination of MSI. The aims of this study were to assess the yield of MSI analysis in families suspected for HNPCC, to compare the results of immunohistochemical staining and MSI analysis, and to assess the additional value of PMS2 staining. EXPERIMENTAL
DESIGN: Clinical data and tumors were collected from 725 individuals from 631 families with suspected HNPCC. MSI analysis was performed using eight markers including the 5 National Cancer Institute markers. Four immunohistochemical staining antibodies were used (MLH1, MSH2, MSH6 and PMS2).
RESULTS: A MSI-H (tumors with instability for >30% of the markers) phenotype in colorectal cancers (CRCs) was observed in 21-49% of families that met the various Bethesda criteria. In families with three cases of CRC diagnosed at age > 50 years, families with a solitary case of CRC diagnosed between ages 45 and 50 years, and families with one CRC case and a first-degree relative with a HNPCC-related cancer, one diagnosed between ages 45 and 50 years (all Bethesda-negative families), the yield of MSI-H was 10-26%. Immunohistochemical staining confirmed the MSI results in 93% of the cases. With IHC, adding PMS2 staining led to the identification of an additional 23% of subjects with an hMLH1 germ-line mutation (35 carriers were tested).
CONCLUSIONS: The Bethesda guidelines for MSI analysis should include families with three or more cases of CRC diagnosed at age > 50 years. The age at diagnosis of CRC in the original guidelines should be raised to 50 years. Routine IHC diagnostics for HNPCC should include PMS2 staining.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14871975     DOI: 10.1158/1078-0432.ccr-0956-3

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  72 in total

1.  Identification of mismatch repair gene mutations in young patients with colorectal cancer and in patients with multiple tumours associated with hereditary non-polyposis colorectal cancer.

Authors:  R C Niessen; M J W Berends; Y Wu; R H Sijmons; H Hollema; M J L Ligtenberg; H E K de Walle; E G E de Vries; A Karrenbeld; C H C M Buys; A G J van der Zee; R M W Hofstra; J H Kleibeuker
Journal:  Gut       Date:  2006-04-24       Impact factor: 23.059

2.  Identification of individuals at risk for Lynch syndrome using targeted evaluations and genetic testing: National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Colorectal Cancer joint practice guideline.

Authors:  Scott M Weissman; Randall Burt; James Church; Steve Erdman; Heather Hampel; Spring Holter; Kory Jasperson; Matt F Kalady; Joy Larsen Haidle; Henry T Lynch; Selvi Palaniappan; Paul E Wise; Leigha Senter
Journal:  J Genet Couns       Date:  2011-12-14       Impact factor: 2.537

Review 3.  Lynch syndrome diagnostics: decision-making process for germ-line testing.

Authors:  E Lastra; M García-González; B Llorente; C Bernuy; M J Barrio; L Pérez-Cabornero; M Durán; C García-Girón
Journal:  Clin Transl Oncol       Date:  2012-04       Impact factor: 3.405

4.  Bethesda criteria for microsatellite instability testing: impact on the detection of new cases of Lynch syndrome.

Authors:  Miguel Serrano; Pedro Lage; Sara Belga; Bruno Filipe; Inês Francisco; Paula Rodrigues; Ricardo Fonseca; Paula Chaves; Isabel Claro; Cristina Albuquerque; António Dias Pereira
Journal:  Fam Cancer       Date:  2012-12       Impact factor: 2.375

5.  Duodenal carcinoma in MUTYH-associated polyposis.

Authors:  M Nielsen; J W Poley; S Verhoef; M van Puijenbroek; M M Weiss; G T Burger; C J Dommering; H F A Vasen; E J Kuipers; A Wagner; H Morreau; F J Hes
Journal:  J Clin Pathol       Date:  2006-08-30       Impact factor: 3.411

Review 6.  The biochemical basis of microsatellite instability and abnormal immunohistochemistry and clinical behavior in Lynch syndrome: from bench to bedside.

Authors:  C Richard Boland; Minoru Koi; Dong K Chang; John M Carethers
Journal:  Fam Cancer       Date:  2007-07-17       Impact factor: 2.375

7.  The added value of PMS2 immunostaining in the diagnosis of hereditary nonpolyposis colorectal cancer.

Authors:  Britta Halvarsson; Annika Lindblom; Eva Rambech; Kristina Lagerstedt; Mef Nilbert
Journal:  Fam Cancer       Date:  2006-07-12       Impact factor: 2.375

Review 8.  Lynch syndrome-associated neoplasms: a discussion on histopathology and immunohistochemistry.

Authors:  Jinru Shia; Susanne Holck; Giovanni Depetris; Joel K Greenson; David S Klimstra
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

9.  Histology of colorectal adenocarcinoma with double somatic mismatch-repair mutations is indistinguishable from those caused by Lynch syndrome.

Authors:  Jessica A Hemminger; Rachel Pearlman; Sigurdis Haraldsdottir; Deborah Knight; Jon Gunnlaugur Jonasson; Colin C Pritchard; Heather Hampel; Wendy L Frankel
Journal:  Hum Pathol       Date:  2018-05-01       Impact factor: 3.466

10.  Colorectal carcinomas in MUTYH-associated polyposis display histopathological similarities to microsatellite unstable carcinomas.

Authors:  Maartje Nielsen; Noel F C C de Miranda; Marjo van Puijenbroek; Ekaterina S Jordanova; Anneke Middeldorp; Tom van Wezel; Ronald van Eijk; Carli M J Tops; Hans F A Vasen; Frederik J Hes; Hans Morreau
Journal:  BMC Cancer       Date:  2009-06-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.